Full-Time

Account Manager

Deadline 5/7/27
Hovione

Hovione

1,001-5,000 employees

CDMO for complex drug APIs manufacturing

Compensation Overview

$120k - $192k/yr

+ Short-term incentive bonus

East Windsor, NJ, USA

In Person

Master's

Category
Sales & Account Management (1)
Required Skills
Sales
Forecasting
CRM
Marketing
Data Analysis

Get referred to Hovione

See people who can refer or advise you

Requirements
  • A Master's degree in Chemistry, Chemical Engineering, or a related field.
  • Typically five years of relevant experience in business development or a related commercial area in the pharmaceutical sector.
  • A technical background is preferred.
  • Experience leading others in a project context.
  • Effective time management skills and the ability to multitask.
  • A track record of overachieving targets.
  • Experience in budget planning and forecasting.
  • Solid knowledge of account management, marketing, sales, and business development principles and practices.
  • Solid knowledge of the pharmaceutical supply chain and market.
  • Solid knowledge of pharmaceutical product development.
  • Solid knowledge of pharmaceutical current Good Manufacturing Practice and regulatory requirements.
  • Good verbal and written communication skills.
  • Skill in managing processes and tools.
  • Fluency in English.
  • Knowledge, experience, and skills to conduct tasks in accordance with established rules and procedures.
Responsibilities
  • Build and maintain effective long-term relationships and high satisfaction with senior-level decision makers and influencers at assigned customer accounts.
  • Identify, develop, and typically close new sales opportunities.
  • Create demand for the organization’s products and services by raising their profile with customers.
  • Achieve revenue targets by increasing revenue spend per account.
  • Negotiate highly complex and long-term contracts with autonomy.
  • Conduct regular status and strategy meetings with customers’ senior management to understand their needs and connect them to product and service strategies.
  • Achieve sales targets and ensure project delivery for the portfolio of customer accounts under responsibility.
  • Manage the client interface of assigned accounts and provide commercial service through timely, trustworthy, and knowledgeable responses to customer demands.
  • Establish relationships with colleagues in different countries and job functions to meet customer needs.
  • Create and execute account management and development plans for assigned accounts.
  • Participate in negotiations of Confidentiality Disclosure Agreements, Master Service Agreements, and Commercial Supply Agreements in collaboration with the Senior Director.
  • Coordinate with global regulatory, production, and research and development groups to provide customer service and technical support.
  • Develop and maintain strong product and service expertise, share knowledge of offerings, and cross-sell as appropriate.
  • Analyze demand and other data in the Customer Relationship Management system for Europe to ensure accurate forecasting and reporting.
  • Assist in negotiating long-term sales, quality, and development agreements.
  • Identify market trends and demands and propose ideas for new products and services.
  • Identify new opportunities for the existing product and service portfolio and coordinate with the Business Development team as appropriate.
  • Monitor customer account and market activity and provide analysis of customer dynamics, market developments, and competitor activity.
  • Optimize relationships with established clients through Key Account Plans, Account Growth Plans, Periodic Business Reviews, client visits, and Satisfaction Survey Action Plans.
  • Develop, issue, and monitor account growth plans for assigned accounts.
  • Prepare reports and data analytics.
  • Attend and represent Hovione at trade shows.
  • Coordinate team members assigned to the area, including recruitment, integration, training needs, and performance management, in accordance with company human resources policies.
  • Develop and propose the activity plan and related budget for the area under responsibility for approval.
  • Monitor the area budget, identify deviations between actual and forecast values, and take corrective measures.
  • Ensure compliance with Good Manufacturing Practice and health, safety, and environmental guidelines and requirements, and promote implementation and maintenance of company policies, systems, and procedures within the assigned team members.
  • Carry out assigned tasks safely and comply with environmental, health, and safety rules, procedures, regulations, and codes of practice.
Desired Qualifications
  • Experience in secondary pharmaceutical activities.
  • Experience in pharmaceutical product development and manufacturing.

Hovione is a contract development and manufacturing organization that helps pharmaceutical companies develop and manufacture active pharmaceutical ingredients (APIs). It specializes in complex chemistry and manufacturing techniques such as particle engineering and spray drying to improve how drugs are absorbed. The company stands out through a long history, a focus on difficult-to-make compounds, and a global footprint with FDA-inspected sites in Portugal, Ireland, China, and the United States, built from a private, family-owned background. Its goal is to enable partners to bring new medicines to market efficiently by providing high-quality, scalable manufacturing capacity and continuous investment in capabilities.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Loures, Portugal

Founded

1959

Get referred to Hovione

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • In July 2026, Hovione reported over 200,000 New Jersey square feet and fall ribbon-cutting.
  • Seixal's €200 million plant targets 2027 opening and extends Portugal capacity.
  • Hovione serves 19 of 20 top pharma clients and exports mainly to America.

What critics are saying

  • Jean-Luc Herbeaux stepped down May 21, 2026, leaving António Almeida and Marco Gil interim.
  • New Jersey's ribbon-cutting hides execution risk; GMP timing slipped from Q2 2026.
  • A failed CEO succession after May 2026 would trigger client defections and a valuation reset.

What makes Hovione unique

  • Hovione's East Windsor spray-drying campus tripled U.S. capacity by July 2026.
  • Its proprietary particle-engineering and continuous tableting expertise supports difficult APIs and inhalation programs.
  • In May 2026, Hovione and IDC launched a commercial intranasal drug-delivery platform.

Help us improve and share your feedback! Did you find this helpful?

Company News

Hovione
Jul 31st, 2026
Continuous Manufacturing Forum 2026.

Continuous Manufacturing Forum 2026. Tuesday, September 22, 2026 Wednesday, September 23, 2026 Location: New Jersey, United States Continuous Tableting is no longer experimental - it is regulated, commercially proven, and rapidly scaling. This September 22-23, Hovione experts will join industry peers at the Continuous Manufacturing Forum (CMF) in Princeton, New Jersey, for two days of scientific exchange focused on the practical implementation of continuous manufacturing in the pharmaceutical industry. This is a must-attend event for those looking to explore the innovations, strategies, and collaborations transforming pharmaceutical production. Join the sessions led by its experts in Continuous Tableting. "The Evolution of Clinical Continuous Manufacturing: From Early Adoption to Operational Maturity" with Anthony Tantuccio "Disrupting the Granulation Paradigm: Enabling Direct Compression of Spray-Dried Dispersions Through Particle Design" with Sarang Oka | Anthony Tantuccio Fellow of Continuous Tableting at Hovione | Sarang Oka Production Senior Manager, Drug Product Continuous Manufacturing | As a first mover CDMO in Continuous Tableting, its team will be available to share firsthand insights into how Hovione can seamlessly integrate CT into your drug product development. Read its latest CT articles: Hovione - The future is continuous.

Contract Pharma
Jul 31st, 2026
Hovione planning ribbon-cutting at NJ facility - A behind-the-scenes preview.

Hovione planning ribbon-cutting at NJ facility - A behind-the-scenes preview. The company is building out more than 200,000 square feet of space in New Jersey. July 31, 2026 Content Marketing Editor Topics.

Jornal de Negócios
Jul 14th, 2026
Hovione invests 200 million in new medicine factory in Seixal by 2027.

Hovione invests 200 million in new medicine factory in Seixal by 2027. On the sidelines of the inauguration of a new production line at the group's campus in Loures, the final stage of a 40 million euro investment cycle, the co-CEOs of Hovione revealed that the development of the group's two industrial complexes has been entirely financed by equity. Hovione is investing 200 million euros in a new unit for the manufacture of medicines in Seixal, in the district of Setúbal, with opening scheduled for September 2027, announced the heads of the Portuguese chemical and pharmaceutical group this Tuesday. On the sidelines of the inauguration of a new production line at the group's campus in Loures, the final stage of a 40 million euro investment cycle, the co-CEOs of Hovione revealed that the development of the group's two industrial complexes has been entirely financed by equity. "We are in the Lisbon region and are a large company, so European funds do not reach us. It is a matter of legislation," said co-CEO António Almeida. As for the Seixal project, although it is located in Greater Lisbon, "it will be covered by the next European framework, from 2028 onwards, but patients cannot wait," added the same official. Despite not having access to European funds, at least in the first phase of the investment, Seixal was chosen to install Hovione's new industrial complex because "it is close to an airport." "Our clients are international, we export all production and we wanted to be close to a center where we could export and easily receive visits," said, in turn, co-CEO Marco Gil, adding that another factor that weighed in the choice was the proximity to Hovione's Research and Development center located in Lumiar, Lisbon. "When we think about these investments, we don't think in terms of 10, 15, 20 years, but rather 50, 60 years. In Seixal, we found a site that had the industrial characteristics necessary for our activity, which allows us to add other technologies, have a much larger scale, and access talent in the Lisbon region but also on the south bank." With the 25% extension of the productive area inaugurated today, Hovione has reached the physical limit of the Loures campus, so the increase in production capacity will pass through the future Seixal complex. The new tablet development and production line will add 50 new skilled jobs to the Loures campus, which already employs around 1,250 workers. With this investment, the Loures campus is strengthened as the main industrial, scientific and technological center of Hovione's global network, which includes among its clients 19 of the 20 largest pharmaceutical companies in the world. Most of Hovione's production is exported abroad, with the USA as the main destination. According to group officials, at least one in every ten medicines approved by the US regulator FDA are produced by Hovione for client pharmaceutical companies. During the inauguration ceremony, where the presidents of AICEP, Madalena Oliveira e Silva, and of the Loures City Council, Ricardo Leão, were also present, the Minister of Economy highlighted the fact that Hovione produces for some of the most sophisticated markets in the world and considered that the pharmaceutical sector "is a strategic sector for Portugal." "The disruptions in international supply chains highlighted the need to strengthen European industrial capacity in essential areas in the field of medicines and health products. It was with this concern that the Government integrated into the PRR measures aimed at strengthening the pharmaceutical sector," he further said. The chemical and pharmaceutical group Hovione was founded more than six decades ago in Portugal by Ivan Villax and Diane Villax. It has four factories in the USA, Portugal, Ireland, and China and development laboratories in Lisbon, Portugal and New Jersey (USA), employing more than 2,600 workers.

Hovione
Jun 18th, 2026
CRS 2026 Annual Meeting.

CRS 2026 Annual Meeting. Monday, July 06, 2026 Thursday, July 09, 2026 Location: Lisbon, Portugal Hovione is presenting at the CRS 2026 Annual Meeting, taking place in Lisbon, Portugal. The conference will explore groundbreaking advancements and transformative ideas in controlled release science and technology. Join the Hovione team for an inspiring week of insightful presentations, engaging discussions, and unparalleled networking opportunities with leading experts and innovators from around the world. Don't miss the chance to speak with its experts and learn how Hovione Scientia Ltd is advancing a differentiated offering in Biologics and Complex Injectables, from early development through to cGMP supply. Hovione Technical Forum. Rational Formulation Strategies for High Concentration Subcutaneous Biologics: From Innovative Excipients to Spray Dried Drug Product Suspensions July 7, 9:00-10:00 AM (WEST) Joana Cristóvão, Ph.D. R&D, Analytical Senior Manager Inês Matos, Ph.D.| R&D, Inhalation & Advanced Drug Delivery Manager Innovative formulation and manufacturing strategies are accelerating the shift from intravenous (IV) to patient-friendly subcutaneous (SC) delivery of biologics. This transition is driven by strong patient preference, reduced healthcare burden, and the opportunity for at-home administration. But challenges remain, especially for high-dose biologics. At the Hovione Technical Forum, in a single session, two complementary presentations will showcase how advanced formulation science and particle engineering are expanding the possibilities for efficient, scalable, and patient-centric biologic therapies: * Learn more about novel excipient design strategies to reduce viscosity and enhance stability in high-concentration liquid formulations * Get insights on spray drying as an enabling technology for biologics, unlocking new solid-state and ultra-concentrated formats Oral presentation. Addressing Nasal Delivery Challenges: Integrated Formulation and Device Strategies for Predictive Performance July 8, 2:53 PM - 3:16 PM WEST Patrícia Henriques, Ph.D. Scientist, Inhalation and Advanced Drug Delivery POSTERS & poster presenter. * (113) Looking Beyond Aerodynamics: Evaluation of Fluticasone Furoate via Dissolution and Permeation using Lung ALIs Beatriz Gamelas, M.Sc.| Ph.D. Candidate, Analytical Development * (132) Why Model Structure Matters: Translatability Across Inhalation PBPK Frameworks Filipa Ferreira, Pharm.D., Ph.D. Senior Scientist II, Translational Lead | Innovation * (502) Innovative Synthetic Sugars for Stable, Low-viscosity High-Concentration Biologic Formulations Joana Cristóvão, Ph.D. R&D, Analytical Senior Manager * (655) Optimizing CRISPR/Cas9 Polymeric Nanoparticle Formulations: From In Silico Insights to Microfluidics and Stability Strategies Andreia Sofia Pereira | Student, Inhalation and Advanced Drug Delivery * (655) CRISPR/Cas9 Nanoparticle Formulations: From In Silico Insights to Microfluidics and Stability Strategies Ask Hovione Scientia Ltd how Hovione Scientia Ltd is advancing more patient centric therapies through proprietary excipients, such as synthetic sugars, and spray dried approaches that unlock alternative dosage forms.

Syenza News
May 15th, 2026
Advancements in Intranasal Drug Delivery: Hovione and IDC launch commercial platform.

Advancements in Intranasal Drug Delivery: Hovione and IDC launch commercial platform. By João L. Carapinha May 15, 2026 Hovione and IDC have announced that their Intranasal Drug Delivery platform has advanced to commercial readiness, with the lead single-use nasal dry powder device now available for partnerships. This integrated solution combines API development, particle engineering, formulation, capsule filling, and device supply, enabling partners to use existing infrastructure while cutting costs, risks, and development timelines. Targeted deposition for systemic and brain Delivery. The platform's single-use device employs a patented mechanism for precise deposition across the nasal cavity, including the upper olfactory region, supporting rapid systemic absorption and potential nose-to-brain pathways. Early patent grants have been secured, and a multi-dose version is in development to expand use across therapies. This approach merges nasal particle engineering with manufacturing and device technologies, improving predictability for complex Intranasal Drug Delivery programs. Efficient manufacturing for nasal powders. Device design and initial manufacturing capabilities are complete, allowing partners to leverage existing capsule-filling lines without major new investment. Complementary in-vitro and analytical tools help address deposition, absorption, and retention challenges. These advances will be presented at the Respiratory Drug Delivery 2026 workshop, highlighting how combined expertise from Hovione and IDC reduces technology transfers and supports scalable production. Lowering barriers to nasal therapy access. By simplifying development and manufacturing, the platform can accelerate commercialization of intranasal therapies and improve health-economic outcomes through greater efficiency and reliability. Hovione and IDC's Intranasal Drug Delivery Platform offers a streamlined path that may enhance patient access and support stronger reimbursement positioning.